Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.

被引：0
|
作者：
Yang, JIwon
Choi, Won-Mook
Kim, Hyung-Don
Choi, Jonggi
Yoo, Changhoon
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
机构：
[1] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Liver Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [21] Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma
    Kim, Hyung-Don
    Park, Young-Gyu
    Kim, Sejin
    Kim, Kyu-Pyo
    Park, Sook-Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 973 - 983
  • [22] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
    Mohri, Kunihide
    Nagai, Hidenari
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
  • [23] Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study
    Storandt, Michael H.
    Zemla, Tyler J.
    Patell, Kanchi
    Naleid, Nikolas
    Gile, Jennifer J.
    Tran, Nguyen H.
    Chakrabarti, Sakti
    Jin, Zhaohui
    Borad, Mitesh
    Mahipal, Amit
    ONCOLOGIST, 2024, 29 (11): : 986 - 996
  • [24] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
    Persano, Mara
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shigeo, Shimose
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Piscaglia, Fabio
    Iavarone, Massimo
    Di Costanzo, Giuseppe
    Marra, Fabio
    Cabibbo, Giuseppe
    Foschi, Francesco
    Siletta, Marianna
    Cascinu, Stefano
    Scartozzi, Mario
    Gardini, Andrea Casadei
    JOURNAL OF HEPATOLOGY, 2023, 78 : S593 - S594
  • [25] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
    Persano, M.
    Rimini, M.
    Toshifumi, T.
    Suda, G.
    Shigeo, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Tovoli, F.
    Piscaglia, F.
    Iavarone, M.
    Marra, F.
    Tamburini, E.
    Cabibbo, G.
    Scartozzi, M.
    Casadei-Gardini, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S6 - S7
  • [26] Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta-analysis
    Zhu, Gang
    Zeng, Longfei
    Yang, Liu
    Zhang, Xin
    Tang, Jinquan
    Pan, Yong
    Li, Bo
    Chen, Mengchen
    Wu, Tao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1425 - 1434
  • [27] Advanced hepatocellular Carcinoma Atezolizumab plus Bevacizumab - new First-Line Therapy Standard
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 429 - 429
  • [28] Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
    Ando, Yuwa
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Johira, Yusuke
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Kosaka, Yumi
    Uchikawa, Shinsuke
    Kodama, Kenichiro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Yamauchi, Masami
    Okamoto, Wataru
    Takahashi, Shoichi
    Imamura, Michio
    Aikata, Hiroshi
    LIVER CANCER, 2023, 12 (03) : 251 - 261
  • [29] Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?
    An, Jihyun
    Shim, Ju H.
    LIVER INTERNATIONAL, 2022, 42 (11) : 2352 - 2353
  • [30] The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib
    Chihiro, Kikukawa
    Kawaoka, Tomokazu
    Uchikawa, Shinsuke
    Kinami, Takahiro
    Yamasaki, Shintaro
    Kosaka, Masanari
    Johira, Yusuke
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Yamaoka, Kenji
    Teraoka, Yuji
    Uchida, Takuro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Miki, Daiki
    Tsuge, Masataka
    Imamura, Michio
    Aikata, Hiroshi
    Oka, Shiro
    ONCOLOGY, 2023, 101 (08) : 491 - 501
12345